Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): Preliminary toxicity results.

Hayes, D. Neil; Raez, L. E.; Sharma, Aarti; Papagikos, Michael A.; Yunus, Furhan; Parvathaneni, Upendra; Eaton, Keith D.; Futran, Neal; Wallace, Stephen S.; Martins, R.

doi:10.1200/jco.2010.28.15_suppl.5580

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another phase II study, 128 patients were assigned randomly to CRT with or without concurrent erlotinib. An interim analysis of the first 100 patients was presented in 2010 at the ASCO meeting.…”

Section: Resultsmentioning

confidence: 99%

Molecular targeting in combination with platinum‐based chemoradiotherapy in head and neck cancer treatment

et al. 2015

View full text Add to dashboard Cite

Supplementing CRT with target therapeutics might only improve survival in some patients with locally advanced HNSCC. Therefore, future studies must address the underlying biological mechanisms that can have an impact on treatment response. Such knowledge is essential in order to facilitate the effective and personalized treatment of patients with locally advanced HNSCC by combining CRT and targeted therapy. © 2015 Wiley Periodicals, Inc. Head Neck 38: E2173-E2181, 2016.

show abstract

Section: Resultsmentioning

confidence: 99%

Molecular targeting in combination with platinum‐based chemoradiotherapy in head and neck cancer treatment

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Hayes et al [ 49 ] randomly assigned 128 patients with LA SCCHN to receive either cisplatin 100 mg/m² on days 1, 22, and 43 combined with 70 Gy of radiotherapy (arm A) or the same treatment plus 150 mg of erlotinib starting one week before CRT and continued until the completion of radiotherapy (arm B). Serious adverse events were observed in 33% and 32% of the patients in arm A and B, respectively.…”

Section: Egfr-directed Therapiesmentioning

confidence: 99%

Biologic Therapy in Head and Neck Cancer: A Road with Hurdles

Specenier

Vermorken

2012

ISRN Oncology

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). A high EGFR expression is associated with an unfavorable prognosis. Cetuximab is a chimeric human/murine IgG1 antibody which binds with high affinity to the EGFR. It is the only targeted agent which got approval for the treatment of SCCHN from the regulatory agencies of Europe and the United States, both in locoregionally advanced disease, in association with radiation, and in recurrent/metastatic disease. The outcome of trials involving other EGFR-directed monoclonal antibodies, that is, zalutumumab and panitumumab, was consistent with the results with cetuximab. However these trials failed to meet their primary endpoint. The results with EGFR-directed tyrosine kinase inhibitors have been disappointing. Other potential targets for treatment in SCCHN include the entire ErbB family, the vascular endothelial growth factor (VEGF) and its receptor (VEGFR), the insulin-like growth factor 1 receptor (IGF-1R), the insulin receptor (IR), histone deacetylases (HDAC), the mammalian target of rapamycin (mTOR), the platelet-derived growth factor receptor (PDGFR), heat-shock protein 90 (HSP90), nuclear factor-kappa B (NF-κB), aurora A or B, and phosphatidylinositol 3-kinase (PIK3CA).

show abstract

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy

Chan

Glenny

Weldon

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): Preliminary toxicity results.

Cited by 7 publications

References 0 publications

Molecular targeting in combination with platinum‐based chemoradiotherapy in head and neck cancer treatment

Molecular targeting in combination with platinum‐based chemoradiotherapy in head and neck cancer treatment

Biologic Therapy in Head and Neck Cancer: A Road with Hurdles

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy

Contact Info

Product

Resources

About